Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Generate Biomedicines, Inc. (GENB)
Somerville, MA, US
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.79% | +12.33% | +21.02% | +22.45% | +22.45% | +22.45% | +22.45% | +22.45% | +22.45% | +22.45% | +22.45% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
25.00
+86.0%
|
| Last Quarter | 1 |
25.00
+86.0%
|
| Last Year | 1 |
25.00
+86.0%
|
| All Time | 1 |
25.00
+86.0%
|
-
Revenue growth Asset Management: +17.4%+55.9% ★
-
EPS growth Asset Management: +22.7%-196.4%
-
FCF margin FCF growth · Asset Management: +27.7%-714.6% Q1'26: -1,165.1%
-
EBIT margin Asset Management: +50.6%-695.0% Q1'26: -887.5%
-
ROIC Asset Management: +6.5%— Q1'26: -402.4%
-
Share dilution Asset Management: +0.0%-60.7% ★
-
Debt / EBITDA Net debt/EBITDA · Asset Management: -0.03×-0.33× Q1'26: -0.27×
| Metric |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 2 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
31.89M
est: 30.30M (+5.3%)
|
25.89M
20.11M – 33.68M
-14.5% YoY
|
23.67M
4.51M – 39.62M
-8.6% YoY
|
92.23M
92.23M – 92.23M
+289.7% YoY
|
22.50M
11.55M – 33.04M
-75.6% YoY
|
163.20M
83.78M – 239.65M
+625.3% YoY
|
| EBITDA |
-208.49M
est: -30.30M (-588.1%)
|
-25.89M
-33.68M – -20.11M
+14.5% YoY
|
-23.67M
-39.62M – -4.51M
+8.6% YoY
|
-92.23M
-92.23M – -92.23M
-289.7% YoY
|
-22.50M
-33.04M – -11.55M
+75.6% YoY
|
-163.20M
-239.65M – -83.78M
-625.3% YoY
|
| EBIT |
-221.67M
est: -30.30M (-631.6%)
|
-25.89M
-33.68M – -20.11M
+14.5% YoY
|
-23.67M
-39.62M – -4.51M
+8.6% YoY
|
-92.23M
-92.23M – -92.23M
-289.7% YoY
|
-22.50M
-33.04M – -11.55M
+75.6% YoY
|
-163.20M
-239.65M – -83.78M
-625.3% YoY
|
| Net Income |
-203.15M
est: -265.44M (+23.5%)
|
-107.49M
-125.76M – -89.21M
+59.5% YoY
|
-108.12M
-123.88M – -92.37M
-0.6% YoY
|
-84.52M
-96.93M – -72.12M
+21.8% YoY
|
-127.48M
-205.11M – -46.83M
-50.8% YoY
|
-109.44M
-176.09M – -40.21M
+14.1% YoY
|
| SGA |
42.26M
est: 51.24M (-17.5%)
|
43.79M
34.01M – 56.95M
-14.5% YoY
|
40.02M
7.62M – 67.01M
-8.6% YoY
|
155.97M
155.97M – 155.97M
+289.7% YoY
|
38.05M
19.53M – 55.87M
-75.6% YoY
|
275.99M
141.68M – 405.27M
+625.3% YoY
|
| EPS |
-4.98
est: -7.57 (+34.2%)
|
-2.16
-2.51 – -1.78
+71.5% YoY
|
-2.15
-2.47 – -1.84
+0.2% YoY
|
-1.69
-1.94 – -1.44
+21.6% YoY
|
-2.55
-4.09 – -0.93
-50.8% YoY
|
-2.19
-3.52 – -0.80
+14.1% YoY
|
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-08 | HC Wainwright & Co. | Buy | Buy | Maintain |
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ARK Genomic Revolution ETF ARKG | 1.08% | 14.07M | 0.75% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.94% | 2.00M | 0.50% |
| 3 | Virtus Biotech Clinical Trials ETF BBC | 0.71% | 410.0K | 0.65% |
| 4 | iShares Russell 2000 Growth ETF IWO | 0.02% | 2.27M | 0.24% |
| 5 | State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc) R2US.L | 0.01% | 733.6K | 0.30% |
| 6 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 374.6K | 0.30% |
| 7 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 35.4K | 0.25% |
| 8 | Global X - Russell 2000 ETF RSSL | 0.01% | 162.9K | 0.08% |
| 9 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 6.2K | 0.39% |
| 10 | iShares Russell 2000 ETF IWM | 0.01% | 9.03M | 0.19% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael T. Nally | CEO & Director | 1M | male |
| Jason E. Silvers | President & CFO | 772.9K | — |
| Gevorg Grigoryan | Co-Founder & CTO | 738.0K | — |
| Dinesh de Alwis | Senior VP & Head of Clinical Drug Development | — | male |
| Kimberly White | Chief Corporate Affairs Officer | — | female |
| Laurie Lee | Chief Medical Officer of Immunology & Inflammation | — | — |
| Molly Gibson | Co-Founder | — | female |
| Noubar Afeyan | Co-founder & Independent Chair of the Board | — | — |
| Sahm Nasseri | Senior Vice President of Business Development & Strategy | — | male |
| Aarif Khakoo | Chief Scientific Officer | — | — |
| Sean W. Martin | Secretary, Chief Legal Officer & General Counsel | — | male |
| Beth Grous | Chief People Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GENB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
